RLYB Stock Price, Rallybio Corporation Quote, Chart

Market Summary

USD1.77-0.09

Delayed

-4.84%

RLYB Stock Price

View Fullscreen

RLYB RSI Chart

RLYB Valuation

Market Cap

73.4M

Price/Earnings (Trailing)

-0.96

Price/Sales (Trailing)

12.62

EV/EBITDA

-0.73

Price/Free Cashflow

-1.29

RLYB Price/Sales (Trailing)

RLYB Profitability

EBT Margin

-1274.50%

Return on Equity

-85.55%

Return on Assets

-76.77%

Free Cashflow Yield

-77.65%

RLYB Fundamentals

RLYB Revenue

Revenue (TTM)

5.8M

Rev. Growth (Yr)

-17.46%

Rev. Growth (Qtr)

-11.88%

RLYB Earnings

Earnings (TTM)

-76.3M

Earnings Growth (Yr)

-9.88%

Earnings Growth (Qtr)

5.99%

Breaking Down RLYB Revenue

Last 7 days

-3.3%

Last 30 days

0.6%

Last 90 days

-11.5%

Trailing 12 Months

-70.2%

How does RLYB drawdown profile look like?

RLYB Financial Health

Current Ratio

9.77

RLYB Investor Care

Shares Dilution (1Y)

9.81%

Diluted EPS (TTM)

-1.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	5.8M	0	0	0
2023	3.4M	0	4.7M	5.6M
2022	134.0K	391.0K	904.0K	2.0M
2021	141.8K	112.5K	83.3K	54.0K
2020	0	0	0	171.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Rallybio Corporation

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 14, 2023	lieber jonathan i	bought	26,050	5.21	5,000	see remarks
Mar 07, 2023	5am partners v, llc	sold	-820,000	8.2	-100,000	-
Mar 07, 2023	parmar kush	sold	-820,000	8.2	-100,000	-
Jun 03, 2022	5am opportunities i, l.p.	sold	-629,112	12.5	-50,329	-
Jun 03, 2022	5am opportunities i, l.p.	sold	-1,245,890	12.5	-99,671	-
Jun 03, 2022	parmar kush	sold	-629,112	12.5	-50,329	-
Jun 03, 2022	parmar kush	sold	-1,245,890	12.5	-99,671	-
May 23, 2022	5am opportunities i, l.p.	sold	-436,189	13.00	-33,553	-
May 23, 2022	5am opportunities i, l.p.	sold	-863,811	13.00	-66,447	-
May 23, 2022	parmar kush	sold	-436,189	13.00	-33,553	-

Which funds bought or sold RLYB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-59,078	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-31.00	-5,603	6,423	-%
May 15, 2024	Laurion Capital Management LP	unchanged	-	-423,032	1,449,270	0.01%
May 15, 2024	MARSHALL WACE, LLP	added	93.22	17,800	53,710	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	453	279,026	364,041	-%
May 15, 2024	HarbourVest Partners LLC	unchanged	-	-11,814	40,472	0.02%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-25.14	-129,145	177,970	-%
May 15, 2024	VIKING GLOBAL INVESTORS LP	unchanged	-	-2,265,180	7,760,340	0.03%
May 15, 2024	Voya Investment Management LLC	sold off	-100	-31,677	-	-%
May 15, 2024	Royal Bank of Canada	reduced	-92.34	-21,000	1,000	-%

Are Funds Buying or Selling RLYB?

Are funds buying RLYB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RLYB

No. of Funds

Unveiling Rallybio Corporation's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	viking global investors lp	11.1%	4,194,777	SC 13G/A
Feb 12, 2024	pivotal bioventure partners fund i, l.p.	6.4%	2,404,644	SC 13D/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 02, 2024	novo holdings a/s	4.7%	1,767,861	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 06, 2023	new leaf ventures iii, l.p.	5.8%	2,147,757	SC 13G/A
Feb 01, 2023	canaan xi l.p.	6.4%	2,059,712	SC 13G/A
Jan 23, 2023	tekla capital management llc	4.6%	1,727,067	SC 13G/A
Nov 17, 2022	novo holdings a/s	6.2%	2,296,007	SC 13G
Jun 07, 2022	5am ventures v, l.p.	7.7%	2,478,969	SC 13D/A

Recent SEC filings of Rallybio Corporation

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 10, 2024	S-3	S-3
May 09, 2024	10-Q	Quarterly Report

Peers (Alternatives to Rallybio Corporation)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Rallybio Corporation News

Latest updates

Rallybio Corporation Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	-11.9%	1,276,000	1,448,000	1,545,000	1,546,000	1,071,000	525,000	270,000	97,000	12,000	12,000	13,000	17,000	29,500	42,000	47,000
Operating Expenses	-6.3%	19,787,000	21,112,000	19,363,000	18,374,000	17,091,000	18,860,000	17,615,000	14,318,000	12,313,000	9,981,000	10,530,000	12,824,000	-	6,710,000	4,662,000
S&GA Expenses	-100.0%	-	5,188,000	6,075,000	7,172,000	6,298,000	6,750,000	7,477,000	6,670,000	6,219,000	5,021,000	3,712,000	3,787,000	-	1,580,000	1,570,000
R&D Expenses	-18.8%	12,936,000	15,924,000	13,288,000	11,202,000	10,793,000	12,110,000	10,138,000	7,648,000	6,094,000	4,960,000	6,818,000	9,037,000	-	5,130,000	3,092,000
EBITDA Margin	1.4%	-12.72	-12.90	-14.66	-19.95	-33.32	-68.16	-136	-348	-840	-298	-220	-175	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	10,000	-	13,000	12,000
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	6.5%	-18,344,000	-19,629,000	-17,726,000	-16,755,000	-15,989,000	-18,237,000	-17,245,000	-14,108,000	-12,192,000	-9,864,000	-10,659,000	-12,793,000	-	-6,629,000	-4,558,000
EBT Margin	1.4%	-12.74	-12.93	-14.70	-20.00	-33.41	-68.34	-136	-349	-842	-299	-221	-175	-	-	-
Net Income	6.0%	-19,029,000	-20,242,000	-18,374,000	-17,318,000	-16,203,000	-18,370,000	-17,583,000	-14,498,000	-12,415,000	-10,196,000	-11,127,000	-13,275,000	-	-7,155,000	-4,893,000
Net Income Margin	1.3%	-13.12	-13.29	-15.05	-20.36	-33.96	-69.54	-139	-359	-870	-317	-235	-186	-	-	-
Free Cashflow	-32.7%	-15,469,000	-11,657,000	-16,471,000	-18,765,000	-15,264,000	-14,739,000	-13,568,000	-13,767,000	-10,023,000	-11,002,000	-12,850,000	-11,991,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-14.1%	99.00	116	133	148	162	180	144	156	169	182	194	120	142
Current Assets	-14.2%	99.00	115	132	147	161	179	142	154	168	181	192	118	141
Cash Equivalents	-21.2%	19.00	24.00	19.00	33.00	40.00	57.00	52.00	61.00	81.00	175	187	113	140
Net PPE	-14.2%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00
Liabilities	8.1%	10.00	9.00	10.00	8.00	7.00	11.00	12.00	8.00	6.00	7.00	7.00	7.00	6.00
Current Liabilities	8.9%	10.00	9.00	9.00	8.00	7.00	11.00	11.00	7.00	6.00	7.00	7.00	7.00	6.00
Shareholder's Equity	-16.0%	89.00	106	124	139	155	169	132	148	163	176	186	113	136
Retained Earnings	-8.1%	-254	-235	-215	-196	-178	-160	-144	-126	-108	-94.03	-81.61	-71.42	-47.01
Additional Paid-In Capital	0.6%	343	341	339	336	333	330	277	274	272	270	268	-	183
Shares Outstanding	0.0%	38.00	38.00	38.00	38.00	38.00	38.00	31.00	30.00	30.00	32.00	28.00	23.00	-
Float	-	-	-	-	134	-	-	-	121	-	108	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-32.7%	-15,457	-11,645	-16,471	-13,384	-18,765	-15,264	-14,735	-13,554	-13,731	-9,886	-10,872	-12,846	-11,929	-	-	-
Share Based Compensation	-18.1%	2,088	2,549	2,634	2,692	3,045	2,294	2,504	2,647	2,054	1,529	1,055	539	522	-	-	-
Cashflow From Investing	-39.3%	10,264	16,909	3,070	6,214	1,465	-30,646	5,772	-7,118	-80,178	-137	-130	-1,504	-562	-	-	-
Cashflow From Financing	-100.0%	-	72.00	-	210	-139	51,157	-79.00	-	-	-1,621	85,251	-663	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RLYB Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 12,936	$ 11,202
General and administrative	6,851	7,172
Total operating expenses	19,787	18,374
Loss from operations	(19,787)	(18,374)
Other income:
Interest income	1,276	1,546
Other income	167	73
Total other income, net	1,443	1,619
Loss before equity in losses of joint venture	(18,344)	(16,755)
Loss on investment in joint venture	685	563
Net loss	$ (19,029)	$ (17,318)
Net loss per common share, basic (in dollars per share)	$ (0.47)	$ (0.43)
Net loss per common share, diluted (in dollars per share)	$ (0.47)	$ (0.43)
Weighted-average common shares outstanding, basic (in shares)	40,773,615	40,248,893
Weighted-average common shares outstanding, diluted (in shares)	40,773,615	40,248,893
Other comprehensive (loss) gain:
Net unrealized (loss) gain on marketable securities	$ (86)	$ 153
Other comprehensive (loss) gain	(86)	153
Comprehensive loss	$ (19,115)	$ (17,165)

RLYB Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 19,301	$ 24,494
Marketable securities	74,874	85,435
Prepaid expenses and other current assets	4,370	4,860
Total current assets	98,545	114,789
Property and equipment, net	211	246
Operating lease right-of-use assets	299	346
Investment in joint venture	304	239
Total assets	99,359	115,620
Current liabilities:
Accounts payable	470	976
Accrued expenses	9,393	8,068
Operating lease liabilities	223	219
Total current liabilities	10,086	9,263
Operating lease liabilities, noncurrent	116	173
Total liabilities	10,202	9,436
Commitments and contingencies (Note 7)
Stockholders' equity
Common stock, $0.0001 par value per share; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; and 37,811,970 and 37,829,565 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	4	4
Preferred stock, $0.0001 par value per share; 50,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; no shares issued or outstanding as of March 31, 2024 and December 31, 2023, respectively	0	0
Additional paid-in capital	343,498	341,410
Accumulated other comprehensive loss	(71)	15
Accumulated deficit	(254,274)	(235,245)
Total stockholders' equity	89,157	106,184
Total liabilities and stockholders' equity	$ 99,359	$ 115,620

About Rallybio Corporation

Rallybio Corporation, a clinical-stage biotechnology company, engages in identifying, accelerating, and development of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

CEO	Dr. Stephen Uden M.B, M.D.
WEBSITE	rallybio.com
INDUSTRY	Biotechnology
EMPLOYEES	45

Rallybio Corporation Frequently Asked Questions

What is the ticker symbol for Rallybio Corporation? What does RLYB stand for in stocks?

RLYB is the stock ticker symbol of Rallybio Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rallybio Corporation (RLYB)?

As of Fri May 17 2024, market cap of Rallybio Corporation is 73.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RLYB stock?

You can check RLYB's fair value in chart for subscribers.

What is the fair value of RLYB stock?

You can check RLYB's fair value in chart for subscribers. The fair value of Rallybio Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Rallybio Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RLYB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Rallybio Corporation a good stock to buy?

The fair value guage provides a quick view whether RLYB is over valued or under valued. Whether Rallybio Corporation is cheap or expensive depends on the assumptions which impact Rallybio Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RLYB.

What is Rallybio Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, RLYB's PE ratio (Price to Earnings) is -0.96 and Price to Sales (PS) ratio is 12.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RLYB PE ratio will change depending on the future growth rate expectations of investors.